Abstract: The invention relates to the field of derivatized cross-linked hyaluronic acid hydrogels having blood-derived proteins linked into their structure, as well as preparation and uses thereof.

Abstract: The invention relates to a new method for increasing proliferation rate of chondrocytes. The present invention is applicable both in research and medicine among others to improve proliferation of chondrocytes without affecting their differentiation status.

Abstract: A method of preparing an isolated serum fraction of platelet rich fibrin, cell cultures comprising said serum fraction and its use as a cell culture additive. The invention also relates to increasing proliferation rate of chondrocytes, to the treatment of articular or joint diseases and to increasing the proliferation rate of mesenchymal stem cells. The isolated serum fraction of platelet rich fibrin (PRF), is prepared by providing platelet rich plasma (PRP) without the addition of an anticoagulant; clotting the PRP to obtain a coagel of PRF; and separating the coagel to isolate the serum fraction which comprises an activated platelet releasate; and further provides for the isolated serum fraction obtained by such method, and its medical use.

Abstract: A blood handling device (1) has a syringe (1(a)) for taking a blood sample, and a container (1(b)) releasably connected to the syringe. The syringe may be used to take a blood sample when the container (1(b)) is disconnected. The container is then re-connected and the full device is centrifuged so that a fraction migrates into a chamber (6) of the container (1(b)). This migration is through a fluid passageway (61, 82) between the syringe volume and the chamber (6). A connector (21) interfaces between the syringe (4, 20) and the container (5), the connector having the fluid passageway (61, 82). The connector has a first part (21(a)) forming a base for the syringe, and a second part (21(b)) arranged to connect to the container (1(b)) during centrifuging and to a cannula after removal of the container.

Abstract: The present invention relates to a tissue substitute material for implantation, comprising (a) a substrate to be implanted covered with (b) a controlled release coating containing (c) at least one biologically substance that decreases bacterial growth, wherein the (b) controlled release coating is a bioavailable, biocompatible polymer material and wherein the (c) at least one biologically active substance that decreases bacterial growth. The present invention also relates to a method to prepare the tissue substitute material, as wells the uses thereof.

Abstract: The present invention relates to a tissue substitute material for implantation, comprising (a) a substrate to be implanted covered with (b) a controlled release coating containing (c) at least one biologically substance that decreases bacterial growth, wherein the (b) controlled release coating is a bioavailable, biocompatible polymer material and wherein the (c) at least one biologically active substance that decreases bacterial growth. The present invention also relates to a method to prepare the tissue substitute material, as wells the uses thereof.

Abstract: The invention relates to pharmaceutical compositions having alkaline pH comprising S-nitrosoglutathione (GSNO) as active ingredient together with usual additives, optionally with one or more polysaccharide-type polymer(s). Another subject of the invention is a method for stabilizing a solution or non-solid composition containing GSNO wherein the pH of the solution or composition is adjusted to an alkaline value.

Abstract: The invention relates to pharmaceutical compositions having alkaline pH comprising S-nitrosoglutathione (GSNO) as active ingredient together with usual additives, optionally with one or more polysaccharide-type polymer(s). Another subject of the invention is a method for stabilizing a solution or non-solid composition containing GSNO wherein the pH of the solution or composition is adjusted to an alkaline value.

Abstract: The invention relates to pharmaceutical compositions comprising S-nitrosoglutathione and one or more polysaccharide-type polimer(s) together with one or more pharmaceutically accepted polymer(s) and additive(s). The invention is based on the discovery that polysaccharide-type polymers (such as chitosan) are capable of stabilizing the otherwise highly labile GSNO.